$ 10.19
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of HELP is 36.9 and suggests 262% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only